Biomerica (BMRA) Stock Price, News & Analysis

Company Overview

Biomerica, Inc. is a medical diagnostics company that develops and commercializes products designed to help diagnose and manage gastrointestinal and other health conditions. The company focuses on tests and related solutions intended to support more personalized treatment decisions.

Biomerica’s best-known product platform is inFoods, which uses blood-based testing to identify foods that may contribute to symptoms associated with gastrointestinal disorders. The company has emphasized inFoods IBS, a diagnostic-guided dietary management solution for people with irritable bowel syndrome, pairing test results with individualized food recommendations.

Biomerica also has developed and marketed diagnostic products for conditions including Helicobacter pylori infection, allergies and respiratory illnesses. Its products have been distributed through healthcare providers and commercial partners in the United States and select international markets. The company is headquartered in Irvine, California, and has been led by Chief Executive Officer Zackary Irani.

Key Stats

• Today's Range: $1.81 to $1.92
• 50-Day Range: $1.52 to $2.78
• 52-Week Range: $1.45 to $3.21
• Volume: 13,846 shs
• Average Volume: 24,558 shs
• Market Capitalization: $5.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Sell

Biomerica Stock Analysis - MarketRank™

Biomerica scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Sell

Consensus Rating

Biomerica has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Biomerica has a consensus price target of $9.00, representing about 389.1% upside from its current price of $1.84.

Amount of Analyst Coverage

Biomerica has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Biomerica has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.09% of the float of Biomerica has been sold short.

Short Interest Ratio / Days to Cover

Biomerica has a short interest ratio ("days to cover") of 0.85, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biomerica has recently decreased by 25.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biomerica does not currently pay a dividend.

Dividend Growth

Biomerica does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.84

News Sentiment

Biomerica has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Biomerica this week, compared to 2 articles on an average week.

Company Ownership

• Score: 4.5 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of Biomerica in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $148,000.00 in company stock, which represents 2.6031% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Biomerica insiders have bought more of their company's stock than they have sold. Specifically, they have bought $148,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

18.00% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

22.28% of the stock of Biomerica is held by institutions.

Company Calendar

• Today: 10/16/2026
• Last Earnings: 10/21/2026
• Next Earnings (Estimated): 10/21/2026
• Fiscal Year End: 5/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:BMRA
• CIK: 73290
• Web: www.biomerica.com
• Phone: (949) 379-2875
• Fax: 949-553-1231
• Employees: 50
• Year Founded: 1971

Price Target and Rating

• Average Price Target for Biomerica: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +389.1%
• Consensus Rating: Sell
• Rating Score (0-4): 1.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.78 million
• Net Margins: -84.79%
• Pretax Margin: -84.26%
• Return on Equity: -97.19%
• Return on Assets: -61.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.62
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: $4.45 million
• Price / Sales: 1.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.85 per share
• Price / Book: 2.16

Miscellaneous

• Outstanding Shares: 3,090,000
• Free Float: 2,534,000
• Market Cap: $5.69 million
• Optionable: No Data
• Beta: 0.38